Analysts See $-0.14 EPS for Moleculin Biotech, Inc. (MBRX)

May 16, 2018 - By Tina Thibodeau

Analysts expect Moleculin Biotech, Inc. (NASDAQ:MBRX) to report $-0.14 EPS on May, 21.They anticipate $0.04 EPS change or 40.00 % from last quarter’s $-0.1 EPS. After having $-0.17 EPS previously, Moleculin Biotech, Inc.’s analysts see -17.65 % EPS growth. The stock decreased 1.14% or $0.02 during the last trading session, reaching $1.72. About 44,458 shares traded. Moleculin Biotech, Inc. (NASDAQ:MBRX) has risen 70.64% since May 16, 2017 and is uptrending. It has outperformed by 59.09% the S&P500.

Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. The company has market cap of $44.33 million. The Company’s lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. It currently has negative earnings. The firm also develops other drugs, including WP1066 Portfolio that focuses on the modulation of regulatory transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma.

More recent Moleculin Biotech, Inc. (NASDAQ:MBRX) news were published by: Nasdaq.com which released: “Moleculin Announces Engagement with Voisin Consulting Life Sciences to Expand Annamycin Clinical Trial” on May 03, 2018. Also Globenewswire.com published the news titled: “Moleculin to Begin Clinical Trials at UMC Southwest Cancer Center” on May 16, 2018. Streetinsider.com‘s news article titled: “Moleculin Biotech (MBRX) Enters Pact with BSP Pharmaceuticals for its Leukemia Drug Candidate” with publication date: April 24, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: